Literature DB >> 16419159

Interleukin-17 levels in Helicobacter pylori-infected gastric mucosa and pathologic sequelae of colonization.

Tomokazu Mizuno1, Takafumi Ando, Kazuo Nobata, Tomoyuki Tsuzuki, Osamu Maeda, Osamu Watanabe, Masaaki Minami, Kenji Ina, Kazuo Kusugami, Richard M Peek, Hidemi Goto.   

Abstract

AIM: To determine the role of interleukin (IL)-17 in gastric ulcerogenesis.
METHODS: Thirty-six gastric ulcer (GU) patients and 29 non-ulcer (NU) patients were enrolled in this study. Mucosal biopsy samples were obtained from the gastric antrum and GU site during endoscopy. Samples were used in in situ stimulation for 48 h in the presence of 10 microg/mL phytohemagglutinin-P (PHA), histological examination, and Helicobacter pylori (H pylori) culture. IL-17 and IL-8 protein levels in culture supernatants were assayed by ELISA. IL-17 mRNA expression was analyzed by reverse transcriptase-polymerase chain reaction (RT-PCR). H pylori cagA and vacA status was assessed by reverse hybridization using a line probe assay (LiPA). IL-8 levels in culture supernatants were assayed after AGS cells were co-cultured with H pylori strain 26,695 or recombinant human (rh) IL-17.
RESULTS: All 36 GU patients and 15 of 29 NU patients were found to be H pylori-positive, while 14 NU patients were H pylori-negative. All 51 H pylori strains from both GU and NU patients were cagA- and vacAs1/m1-positive. Antral mucosal tissues from H pylori-positive patients contained significantly (H pylori-positive NU patients: median 467 pg/mg/protein, range 53-2,499; H pylori-negative NU patients: median 104 pg/mg/protein, range 16-312, P< 0.0005) higher levels of IL-17 than those from uninfected patients. IL-17 levels at the ulcer site were significantly (ulcer site: median 1,356 pg/mg/protein, range 121-1,3730; antrum: median 761 pg/mg/protein, range 24-7,620, P< 0.005) higher than those at distant sites in the antrum. Biopsies from H pylori-positive GU and NU patients showed IL-17 mRNA expression in all samples whereas those from the antrum of the H pylori-negative controls showed no detectable expression. A significant correlation was seen between IL-17 and IL-8 levels at each biopsy site (ulcer: r = 0.62, P< 0.0001; antrum: r = 0.61, P< 0.0001) in GU patients. RhIL-17 and H pylori strain 26,695 each stimulated IL-8 production from AGS cells.
CONCLUSION: IL-17 may play an important role in the inflammatory response to H pylori colonization, and may ultimately influence the outcome of H pylori-associated diseases that arise within the context of gastritis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16419159      PMCID: PMC4320334          DOI: 10.3748/wjg.v11.i40.6305

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  45 in total

1.  Hypothesis: the changing relationships of Helicobacter pylori and humans: implications for health and disease.

Authors:  M J Blaser
Journal:  J Infect Dis       Date:  1999-06       Impact factor: 5.226

Review 2.  Interleukin-17 and its receptor.

Authors:  M K Spriggs
Journal:  J Clin Immunol       Date:  1997-09       Impact factor: 8.317

3.  Mouse IL-17: a cytokine preferentially expressed by alpha beta TCR + CD4-CD8-T cells.

Authors:  J Kennedy; D L Rossi; S M Zurawski; F Vega; R A Kastelein; J L Wagner; C H Hannum; A Zlotnik
Journal:  J Interferon Cytokine Res       Date:  1996-08       Impact factor: 2.607

4.  Mucosal IgA recognition of Helicobacter pylori 120 kDa protein, peptic ulceration, and gastric pathology.

Authors:  J E Crabtree; J D Taylor; J I Wyatt; R V Heatley; T M Shallcross; D S Tompkins; B J Rathbone
Journal:  Lancet       Date:  1991-08-10       Impact factor: 79.321

5.  IL-17 stimulates intraperitoneal neutrophil infiltration through the release of GRO alpha chemokine from mesothelial cells.

Authors:  J Witowski; K Pawlaczyk; A Breborowicz; A Scheuren; M Kuzlan-Pawlaczyk; J Wisniewska; A Polubinska; H Friess; G M Gahl; U Frei; A Jörres
Journal:  J Immunol       Date:  2000-11-15       Impact factor: 5.422

Review 6.  Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis.

Authors:  Alexander C Ford; Brendan C Delaney; David Forman; Paul Moayyedi
Journal:  Am J Gastroenterol       Date:  2004-09       Impact factor: 10.864

Review 7.  Defining Helicobacter pylori as a pathogen: strain heterogeneity and virulence.

Authors:  H L Mobley
Journal:  Am J Med       Date:  1996-05-20       Impact factor: 4.965

Review 8.  Interleukin-17 and the interleukin-17 family member network.

Authors:  Shu-Hai Huang; Stavros Frydas; Duraisamy Kempuraj; Renato C Barbacane; Alfredo Grilli; William Boucher; Richard Letourneau; Bhuvaneshwari Madhappan; Nikoletta Papadopoulou; Nicola Verna; Maria Anna De Lutiis; Teresa Iezzi; Graziano Riccioni; Theoharis C Theoharides; Pio Conti
Journal:  Allergy Asthma Proc       Date:  2004 Jan-Feb       Impact factor: 2.587

Review 9.  Interleukin-17.

Authors:  F Fossiez; J Banchereau; R Murray; C Van Kooten; P Garrone; S Lebecque
Journal:  Int Rev Immunol       Date:  1998       Impact factor: 5.311

10.  Divergence of genetic sequences for the vacuolating cytotoxin among Helicobacter pylori strains.

Authors:  T L Cover; M K Tummuru; P Cao; S A Thompson; M J Blaser
Journal:  J Biol Chem       Date:  1994-04-08       Impact factor: 5.157

View more
  40 in total

1.  IFN-γ inhibits gastric carcinogenesis by inducing epithelial cell autophagy and T-cell apoptosis.

Authors:  Shui Ping Tu; Michael Quante; Govind Bhagat; Shigeo Takaishi; Guanglin Cui; Xiang Dong Yang; Sureshkumar Muthuplani; Wataru Shibata; James G Fox; D Mark Pritchard; Timothy C Wang
Journal:  Cancer Res       Date:  2011-04-21       Impact factor: 12.701

2.  Emerging role of IL-23/IL-17 axis in H pylori-associated pathology.

Authors:  Roberta Caruso; Francesco Pallone; Giovanni Monteleone
Journal:  World J Gastroenterol       Date:  2007-11-14       Impact factor: 5.742

Review 3.  Th17 Cells in Helicobacter pylori Infection: a Dichotomy of Help and Harm.

Authors:  Beverly R E A Dixon; Rafat Hossain; Rachna V Patel; Holly M Scott Algood
Journal:  Infect Immun       Date:  2019-10-18       Impact factor: 3.441

Review 4.  Inflammation and gastrointestinal Candida colonization.

Authors:  Carol A Kumamoto
Journal:  Curr Opin Microbiol       Date:  2011-07-28       Impact factor: 7.934

5.  Interleukin-17C in Human Helicobacter pylori Gastritis.

Authors:  Shingo Tanaka; Hiroyuki Nagashima; Modesto Cruz; Tomohisa Uchida; Takahiro Uotani; José A Jiménez Abreu; Varocha Mahachai; Ratha-Korn Vilaichone; Thawee Ratanachu-Ek; Lotay Tshering; David Y Graham; Yoshio Yamaoka
Journal:  Infect Immun       Date:  2017-09-20       Impact factor: 3.441

6.  Therapy with omeprazole modulates regulatory T cell/T helper 17 immune response in children with duodenal ulcers.

Authors:  Chuan-Ying Li; Cheng Wu
Journal:  Inflammopharmacology       Date:  2017-07-22       Impact factor: 4.473

7.  Epicutaneous model of community-acquired Staphylococcus aureus skin infections.

Authors:  Ranjani Prabhakara; Oded Foreman; Roberto De Pascalis; Gloria M Lee; Roger D Plaut; Stanley Y Kim; Scott Stibitz; Karen L Elkins; Tod J Merkel
Journal:  Infect Immun       Date:  2013-02-04       Impact factor: 3.441

8.  IL-17 and anti-bacterial immunity: protection versus tissue damage.

Authors:  Andrea M Cooper
Journal:  Eur J Immunol       Date:  2009-03       Impact factor: 5.532

Review 9.  Impairment of ghrelin synthesis in Helicobacter pylori-colonized stomach: new clues for the pathogenesis of H. pylori-related gastric inflammation.

Authors:  Omero Alessandro Paoluzi; Del Vecchio Giovanna Blanco; Roberta Caruso; Ivan Monteleone; Giovanni Monteleone; Francesco Pallone
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

10.  Increased expression of IL17A in human gastric cancer and its potential roles in gastric carcinogenesis.

Authors:  Xiaoqin Wu; Zhirong Zeng; Lixia Xu; Jun Yu; Qinghua Cao; Minhu Chen; Joseph J Y Sung; Pinjin Hu
Journal:  Tumour Biol       Date:  2014-02-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.